TVARDI THERAPEUTICS, INC. Excess Tax Benefit from Share-based Compensation, Financing Activities
TVARDI THERAPEUTICS, INC. (TVRD) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2022-03-01
- TVARDI THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-12-31 was $0.00.
- TVARDI THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-09-30 was $0.00.
- TVARDI THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-12-31 was $0.00.
- TVARDI THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-09-30 was $0.00.
- TVARDI THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2021 was $0.00.
- TVARDI THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2020 was $0.00.
- TVARDI THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2019 was $0.00.
- TVARDI THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2018 was $0.00.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $0.00 derived: sum of 2 quarters · filed 2019-03-12 | $0.00 10-K · filed 2019-03-12 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $0.00 10-Q · filed 2016-11-04 | ||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-04 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $0.00 derived: sum of 2 quarters · filed 2018-03-15 | $0.00 10-K · filed 2018-03-15 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $0.00 10-Q · filed 2016-11-04 | ||
| 2015-06-30 | $0.00 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |